Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 21 | 2024 | 153 | 5.900 |
Why?
|
| Immunotherapy, Adoptive | 23 | 2024 | 184 | 4.910 |
Why?
|
| Antigens, CD19 | 12 | 2024 | 41 | 2.380 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 12 | 2024 | 879 | 2.380 |
Why?
|
| Lymphoma, Mantle-Cell | 4 | 2024 | 37 | 2.030 |
Why?
|
| Lymphoma, Follicular | 5 | 2024 | 72 | 1.680 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2023 | 261 | 1.380 |
Why?
|
| Lymphoma, B-Cell | 5 | 2022 | 104 | 1.280 |
Why?
|
| Transplantation, Autologous | 7 | 2024 | 340 | 1.270 |
Why?
|
| Standard of Care | 2 | 2024 | 63 | 0.980 |
Why?
|
| Oncologists | 1 | 2023 | 36 | 0.910 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2024 | 84 | 0.830 |
Why?
|
| Blood Component Removal | 1 | 2020 | 24 | 0.760 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2024 | 1343 | 0.760 |
Why?
|
| Jehovah's Witnesses | 1 | 2021 | 19 | 0.760 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2018 | 125 | 0.760 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 190 | 0.740 |
Why?
|
| Lymphoma | 3 | 2024 | 264 | 0.730 |
Why?
|
| Transplantation Conditioning | 3 | 2021 | 371 | 0.720 |
Why?
|
| Biological Products | 4 | 2023 | 146 | 0.720 |
Why?
|
| Humans | 55 | 2024 | 87555 | 0.640 |
Why?
|
| Receptors, Antigen, T-Cell | 6 | 2024 | 382 | 0.630 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 2508 | 0.550 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2016 | 77 | 0.540 |
Why?
|
| Graft vs Host Disease | 3 | 2023 | 357 | 0.490 |
Why?
|
| Hepatitis B virus | 1 | 2014 | 44 | 0.480 |
Why?
|
| Hepatitis B | 1 | 2014 | 76 | 0.460 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 730 | 0.440 |
Why?
|
| Retrospective Studies | 10 | 2024 | 8713 | 0.430 |
Why?
|
| Geriatric Assessment | 3 | 2024 | 180 | 0.420 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1412 | 0.410 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2023 | 139 | 0.400 |
Why?
|
| Remission Induction | 5 | 2024 | 730 | 0.400 |
Why?
|
| Aged | 20 | 2024 | 18644 | 0.390 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2023 | 190 | 0.360 |
Why?
|
| Cell- and Tissue-Based Therapy | 4 | 2023 | 49 | 0.350 |
Why?
|
| Prognosis | 4 | 2024 | 3708 | 0.350 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 2384 | 0.330 |
Why?
|
| Adult | 17 | 2024 | 26018 | 0.320 |
Why?
|
| Middle Aged | 18 | 2024 | 25343 | 0.320 |
Why?
|
| T-Lymphocytes | 4 | 2021 | 1205 | 0.290 |
Why?
|
| Sarcopenia | 2 | 2016 | 13 | 0.280 |
Why?
|
| Male | 20 | 2024 | 41502 | 0.250 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 24 | 0.240 |
Why?
|
| Oleic Acids | 1 | 2023 | 26 | 0.230 |
Why?
|
| Female | 19 | 2024 | 45191 | 0.230 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2023 | 9 | 0.230 |
Why?
|
| Candidiasis | 1 | 2023 | 36 | 0.230 |
Why?
|
| Survival Analysis | 3 | 2023 | 1535 | 0.220 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 139 | 0.210 |
Why?
|
| Rituximab | 4 | 2016 | 117 | 0.210 |
Why?
|
| Veterans | 4 | 2016 | 83 | 0.210 |
Why?
|
| Tumor Burden | 1 | 2023 | 301 | 0.210 |
Why?
|
| Hodgkin Disease | 1 | 2023 | 179 | 0.200 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 185 | 0.190 |
Why?
|
| 5-Methylcytosine | 1 | 2022 | 113 | 0.190 |
Why?
|
| United States | 7 | 2023 | 6769 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 942 | 0.180 |
Why?
|
| Recurrence | 4 | 2024 | 1162 | 0.180 |
Why?
|
| Cladribine | 1 | 2019 | 35 | 0.180 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 45 | 0.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 582 | 0.170 |
Why?
|
| Carcinoma | 1 | 2023 | 440 | 0.170 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 334 | 0.170 |
Why?
|
| Patient Selection | 2 | 2019 | 682 | 0.170 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 130 | 0.170 |
Why?
|
| Neoplasms | 2 | 2023 | 2970 | 0.160 |
Why?
|
| Disease Management | 1 | 2019 | 321 | 0.150 |
Why?
|
| Preoperative Care | 1 | 2019 | 399 | 0.150 |
Why?
|
| Patient Care Team | 1 | 2019 | 280 | 0.150 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 266 | 0.140 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 318 | 0.140 |
Why?
|
| Obesity, Abdominal | 1 | 2016 | 8 | 0.140 |
Why?
|
| Cyclophosphamide | 4 | 2021 | 300 | 0.140 |
Why?
|
| Body Composition | 1 | 2016 | 69 | 0.140 |
Why?
|
| Up-Regulation | 1 | 2018 | 725 | 0.130 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 271 | 0.130 |
Why?
|
| Stem Cell Transplantation | 3 | 2021 | 185 | 0.130 |
Why?
|
| Adolescent | 3 | 2024 | 9080 | 0.130 |
Why?
|
| Anthracyclines | 1 | 2015 | 37 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
| Doxorubicin | 4 | 2016 | 297 | 0.120 |
Why?
|
| Febrile Neutropenia | 1 | 2014 | 14 | 0.120 |
Why?
|
| Survivors | 1 | 2016 | 233 | 0.120 |
Why?
|
| Treatment Outcome | 6 | 2024 | 8054 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 747 | 0.120 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 6613 | 0.120 |
Why?
|
| Heart Failure | 1 | 2023 | 1157 | 0.120 |
Why?
|
| Venous Thromboembolism | 1 | 2016 | 157 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 776 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1138 | 0.110 |
Why?
|
| Transplantation, Homologous | 3 | 2020 | 994 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1232 | 0.110 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2023 | 86 | 0.110 |
Why?
|
| Time Factors | 1 | 2021 | 5262 | 0.110 |
Why?
|
| Vincristine | 3 | 2016 | 112 | 0.100 |
Why?
|
| Young Adult | 4 | 2024 | 6117 | 0.100 |
Why?
|
| Prednisone | 3 | 2016 | 258 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2014 | 762 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2014 | 513 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2021 | 855 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1393 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2023 | 4232 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 3640 | 0.070 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2024 | 4 | 0.060 |
Why?
|
| Dairy Products | 1 | 2023 | 11 | 0.060 |
Why?
|
| Red Meat | 1 | 2023 | 10 | 0.060 |
Why?
|
| Lymphoma, T-Cell | 1 | 2024 | 52 | 0.060 |
Why?
|
| Fatty Acids, Volatile | 1 | 2023 | 32 | 0.060 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2023 | 66 | 0.060 |
Why?
|
| Milk | 1 | 2023 | 53 | 0.060 |
Why?
|
| Sheep | 1 | 2023 | 251 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2023 | 108 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2023 | 222 | 0.060 |
Why?
|
| Cattle | 1 | 2023 | 376 | 0.060 |
Why?
|
| Troponin | 1 | 2023 | 25 | 0.060 |
Why?
|
| Cyclic AMP | 1 | 2023 | 274 | 0.050 |
Why?
|
| Melphalan | 1 | 2023 | 98 | 0.050 |
Why?
|
| Outpatients | 1 | 2023 | 98 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2023 | 141 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2024 | 271 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 192 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 260 | 0.050 |
Why?
|
| Thiotepa | 1 | 2021 | 32 | 0.050 |
Why?
|
| Histiocytes | 1 | 2021 | 22 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2023 | 313 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 264 | 0.050 |
Why?
|
| Incidence | 2 | 2016 | 1569 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2021 | 152 | 0.050 |
Why?
|
| Risk Factors | 2 | 2024 | 5373 | 0.050 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 22 | 0.040 |
Why?
|
| Survival Rate | 1 | 2024 | 1870 | 0.040 |
Why?
|
| Chimerism | 1 | 2020 | 36 | 0.040 |
Why?
|
| Filgrastim | 1 | 2019 | 56 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 50 | 0.040 |
Why?
|
| Hydrazines | 1 | 2019 | 30 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 2020 | 83 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 56 | 0.040 |
Why?
|
| Mice | 2 | 2023 | 11586 | 0.040 |
Why?
|
| Triazoles | 1 | 2019 | 98 | 0.040 |
Why?
|
| Cytarabine | 1 | 2019 | 219 | 0.040 |
Why?
|
| Animals | 3 | 2023 | 26951 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 608 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 492 | 0.040 |
Why?
|
| Palliative Care | 1 | 2019 | 262 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 267 | 0.040 |
Why?
|
| Steroids | 1 | 2018 | 175 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2020 | 486 | 0.040 |
Why?
|
| Biomarkers | 1 | 2023 | 1733 | 0.040 |
Why?
|
| Abdominal Fat | 1 | 2016 | 13 | 0.040 |
Why?
|
| Subcutaneous Fat | 1 | 2016 | 19 | 0.040 |
Why?
|
| Neutropenia | 1 | 2016 | 215 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2791 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2015 | 114 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 852 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 461 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1021 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1031 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 3161 | 0.030 |
Why?
|
| Hospitalization | 1 | 2016 | 858 | 0.020 |
Why?
|
| Mutation | 1 | 2022 | 4061 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2618 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3407 | 0.020 |
Why?
|